About CJC-1295 with Ipamorelin
CJC-1295 and Ipamorelin are two distinct research peptides frequently studied together for their complementary effects on growth hormone signalling. CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), studied for its action at the GHRH receptor and its role in stimulating pulsatile growth hormone release. Ipamorelin, by contrast, is a selective growth hormone secretagogue (GHS) that acts at the ghrelin receptor (GHS-R1a) — a separate signalling pathway associated with growth hormone secretion. For a closer look at Ipamorelin on its own, see our standalone Ipamorelin research peptide.
Because the two compounds act on different receptors within the same broader growth-hormone-release pathway, researchers have studied their combined use to examine complementary signalling effects compared with either compound investigated alone. This pairing is one of the more frequently referenced combinations in growth hormone secretagogue research literature.
This product supplies CJC-1295 and Ipamorelin together as a combined 10 mg vial of lyophilised powder. For related compounds, see our peptide Compound Library.